This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Therapeutic use

Authoring team

Lamotrigine can be used as monotherapy or as additional therapy for patients whose seizures are resistant to first-line antiepileptic drugs.

Slow introduction of the drug is preferred by some:

  • in patients taking sodium valproate:
    • begin with 25 mg on alternate days for 2 weeks,
    • then 25 mg/day for 2 weeks,
    • then increase stepwise to maintenance dose of 50-100 mg/day

  • for other patients:
    • begin with 50 mg/day,
    • increase after 2 weeks to 50 mg bd,
    • then by 100 mg/day increments monthly as necessary to a maintenance dose of around 200 mg bd

If the drug is discontinued then it should be withdrawn slowly (to avoid the risk of rebound seizures). If the patient is taking sodium valproate then it should be reduced by 25 mg/week. If the patient is taking other anticonvulsants then reduction of 50-100 mg/week is recommended.

Before prescribing this medication the current doseage recommendations should be consulted.

Ref: Prescribers' Journal (1998), 38(2), 98-106.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.